Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.60 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | CCR6 | P51684 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ncx-4016 SCHEMBL19524 | 0.89 | PTGS2 (0.57) | PTGS2ALOX5HSD17B10KDM4ELMNA | |
| Ncx-4016 SCHEMBL29813476 | 0.89 | PTGS2 (0.57) | PTGS2ALOX5HSD17B10KDM4ELMNA | |
| Ncx-4016 SCHEMBL29546681 | 0.89 | PTGS2 (0.57) | PTGS2ALOX5HSD17B10KDM4ELMNA | |
| SCHEMBL4328024 | 0.85 | PTGS2 (0.54) | PTGS2ALOX5HSD17B10KDM4ELMNA | |
| SCHEMBL12268174 | 0.81 | PTGS2 (0.60) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| SCHEMBL16010711 | 0.80 | PTGS2 (0.53) | PTGS2ALOX5HSD17B10KDM4ELMNA | |
| SCHEMBL2547980 | 0.80 | PTGS2 (0.62) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| SCHEMBL15889887 | 0.80 | PTGS2 (0.85) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| SCHEMBL4335260 | 0.79 | PTGS2 (0.57) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| SCHEMBL4325931 | 0.79 | PTGS2 (0.57) | PTGS2HSD17B10KDM4ELMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1526839-B1 | ORAL PHARMACEUTICAL FORMS OF LIQUID DRUGS HAVING IMPROVED BIOAVAILABILITY | NICOX SA (FR) | 2007-03-14 | — | — | EP | claimed |
| US-20060171969-A1 | Oral pharmaceutical forms of liquid drugs having improved bioavailability | NICOX S.A. (FR) | 2006-08-03 | — | — | US | claimed |
| EP-1526839-A1 | ORAL PHARMACEUTICAL FORMS OF LIQUID DRUGS HAVING IMPROVED BIOAVAILABILITY | Nicox S.A. (FR) | 2005-05-04 | — | — | EP | claimed |
| WO-2004000273-A1 | ORAL PHARMACEUTICAL FORMS OF LIQUID DRUGS HAVING IMPROVED BIOAVAILABILITY | NICOX S.A. (FR) | 2003-12-31 | — | — | WO | claimed |
| EP-1526839-B1 | ORAL PHARMACEUTICAL FORMS OF LIQUID DRUGS HAVING IMPROVED BIOAVAILABILITY | NICOX SA (FR) | 2007-03-14 | — | — | EP | disclosed |
| US-20060171969-A1 | Oral pharmaceutical forms of liquid drugs having improved bioavailability | NICOX S.A. (FR) | 2006-08-03 | — | — | US | disclosed |
| EP-1526839-A1 | ORAL PHARMACEUTICAL FORMS OF LIQUID DRUGS HAVING IMPROVED BIOAVAILABILITY | Nicox S.A. (FR) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004000273-A1 | ORAL PHARMACEUTICAL FORMS OF LIQUID DRUGS HAVING IMPROVED BIOAVAILABILITY | NICOX S.A. (FR) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060171969-A1 | Oral pharmaceutical forms of liquid drugs having improved bioavailability | ABCG2, SLCO1B1, SLCO4C1 | PTGS2 653/4885ALOX5 613/4885HSD17B10 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.